SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)
[Item 5.07. ach of the seven (7) director-nominees: Name of Nominee Votes For]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: Item 5.07. ach of the seven (7) director-nominees:
[Item 5.07. ach of the seven (7) director-nominees: Name of Nominee Votes For]
CCCL [China Ceramics] 6-K: (Original Filing)
[Copy of correspondence to: Stuart Management Company 33 Riverside Avenue th 5 Westport, CT 06880 x ¨ Form 20-F ¨ ¨ ¨ x Yes EXPLANATORY NOTE 2 CHINA CERAMICS CO., LTD. AND ITS SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (RMB in thousands, except EPS and share data) Six months ended June 30,]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Receives SFDA Approval to Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine BEIJING, December 28, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand,] [BEIJING, December 31, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its common shares will be listed on the NASDAQ Global Select Market effective January 3, 2011. The Company received notification from the NASDAQ Stock Market dated December 7, 2010 that as part of the exchanges annual review of Global] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Receives SFDA Approval to Commence Clinical Trials
[Sinovac Receives SFDA Approval to Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine BEIJING, December 28, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand,] [BEIJING, December 31, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its common shares will be listed on the NASDAQ Global Select Market effective January 3, 2011. The Company received notification from the NASDAQ Stock Market dated December 7, 2010 that as part of the exchanges annual review of Global] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
CTC [IFM Investments] 6-K: (Original Filing)
[This Form 6-K consists of: on the regional business updates An announcement]
CTC [IFM Investments] 6-K: This Form 6-K consists of: on the regional
[This Form 6-K consists of: on the regional business updates An announcement]
DANG [E-COMMERCE CHINA DANGDANG] S-8: (Original Filing)
[] [Our ref DLK\274965\4256289v2 E-Commerce China Dangdang Inc. 4 January 2011 Dear Sirs E-Commerce China Dangdang Inc. Company Registration Statement Shares Plans We have examined the Registration Statement on Form S-8 to be filed by E-Commerce China Dangdang Inc., a Cayman Islands exempted company incorporated with limited liability (the 2004 Share Incentive Plan 2010 Share Incentive Plan As Cayman Islands] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-23.1 3 h04726exv23w1.htm EX-23.1 CONSENT OF ERNST & YOUNG HUA MING]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)
[Item 5.07. ach of the seven (7) director-nominees: Name of Nominee Votes For Votes Withheld Weibing Lu 3,175,125 9,912 Wei Wen 3,175,125 9,912 Mark D. Chen 3,043,441 141,596 R.ott Cramer 3,175,125 9,912 Qiang Fan 3,177,079 7,958 Chengtun Qu 3,182,079 2,958 Shouguo Zhao 3,177,079 7,958ystar Bio-Pharmaceuticalmpany Weibing Lu Chief Executive Officer]
